Observations placeholder
Zemplar
Identifier
020396
Type of Spiritual Experience
Background
A description of the experience
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed under the trade name Zemplar) is a drug used for the prevention [sic] and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (Ergocalciferol).
Adverse effects by frequency:
Very common (>10% frequency):
- Nausea
Common (1-10% frequency):
- Diarrhoea†
- Oedema
- Allergic reaction
- Arthritis
- Dizziness†
- Stomach discomfort‡
- Gastroesophageal reflux disease†
- Acne†
- Hypercalcaemia†
- Hypocalcaemia†
- Hyperphosphataemia
- Decreased appetite†
- Headache
- Breast tenderness†
- Taste changes
- Hypoparathyroidism
- Vertigo
- Rash‡
Uncommon (0.1-1% frequency):
- Abnormal hepatic enzymes‡
- Constipation‡
- Dry mouth‡
- Itchiness‡
- Hives
- Hypersensitivity‡
- Muscle spasms‡
- Bleeding time prolonged
- Aspartate aminotransferase increased
- Laboratory test abnormal
- Weight loss
- Elevated blood creatinine
- Cardiac arrest
- Arrhythmia
- Atrial flutter
- Anaemia
- Leucopenia
- Lymphadenopathy
- Coma
- Stroke
- Transient ischemic attack
- Fainting
- Myoclonus
- Hypoaesthesia
- Paraesthesia
- Glaucoma
- Conjunctivitis
- Ear disorder
- Pulmonary oedema
- Asthma
- Shortness of breath
- Nose bleed
- Cough
- Rectal haemhorrhage
- Colitis
- Gastritis
- Indigestion
- Difficulty swallowing
- Gastrointestinal disorder
- Gastrointestinal haemorrhage
- Bullous dermatitis
- Hair loss
- Hirsutism
- Hyperhidrosis
- Joint pain
- Joint stiffness
- Back pain
- Muscle twitching
- Muscle aches
- Hyperparathyroidism
- Hyperkalaemia
- Hypocalcemia
- Breast cancer
- Sepsis
- Pneumonia
- Infection
- Pharyngitis
- Vaginal infection
- Influenza
- High blood pressure
- Hypotension
- Gait disturbance
- Injection site pain
- Fever
- Chest pain
- Condition aggravated
- Muscle weakness
- Malaise
- Thirst
- Breast pain
- Impotence
- Confusional state
- Delirium
- Depersonalization
- Agitation
- Insomnia
- Nervousness
‡ These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease.
† These are adverse effects only seen in patients with grade 5 chronic kidney disease.
On Jan, 14, 2017 11,821 people reported to have side effects when taking Zemplar.
Among them, 10 people (0.08%) have Hallucination
Time on Zemplar when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Feb, 18, 2016: 4,351 people reported to have side effects when taking Zemplar. Among them, 208 people (4.78%) have Death.
Time on Zemplar when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 37.84% | 27.03% | 21.62% | 10.81% | 2.70% | 0.00% | 0.00% |
Gender of people who have Death when taking Zemplar :
Female | Male | |
Death | 45.63% | 54.37% |
Age of people who have Death when taking Zemplar :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 2.56% | 1.71% | 16.24% | 79.49% |
Top conditions involved for these people :
- Hyperparathyroidism secondary (60 people, 28.85%)
- Renal failure chronic (30 people, 14.42%)
- Hyperparathyroidism (23 people, 11.06%)